 Chemical Structure.png)
Nateglinide (formerly A-4166; trade names: Fastic, Starlix), a meglitinide analog, is a potent and orally bioavailable antihyperglycemic medication used for treating type 2 diabetes [non-insulin-dependent diabetes mellitus (NIDDM)]. It lowers blood glucose levels by acting as an insulin secretagog agent which stimulates insulin secretion from the pancreas. It is a short-acting insulin secretagogue that inhibits ATP-sensitive K+ channels in pancreatic β-cells, which depolarizes the β cells and opens voltage-gated calcium channels, leading to calcium influx and fusion of insulin-containing vesicles with the cell membrane, and insulin secretion occurs.
Physicochemical Properties
| Molecular Formula | C19H27NO3 | |
| Molecular Weight | 317.42 | |
| Exact Mass | 317.199 | |
| CAS # | 105816-04-4 | |
| Related CAS # | Nateglinide-d5;1227666-13-8 | |
| PubChem CID | 5311309 | |
| Appearance | White to off-white solid powder | |
| Density | 1.1±0.1 g/cm3 | |
| Boiling Point | 527.6±39.0 °C at 760 mmHg | |
| Melting Point | 137-141ºC | |
| Flash Point | 272.9±27.1 °C | |
| Vapour Pressure | 0.0±1.5 mmHg at 25°C | |
| Index of Refraction | 1.536 | |
| LogP | 4.21 | |
| Hydrogen Bond Donor Count | 2 | |
| Hydrogen Bond Acceptor Count | 3 | |
| Rotatable Bond Count | 6 | |
| Heavy Atom Count | 23 | |
| Complexity | 393 | |
| Defined Atom Stereocenter Count | 1 | |
| SMILES | CC(C)C1CCC(CC1)C(=O)N[C@H](CC2=CC=CC=C2)C(=O)O |
|
| InChi Key | OELFLUMRDSZNSF-BRWVUGGUSA-N | |
| InChi Code | InChI=1S/C19H27NO3/c1-13(2)15-8-10-16(11-9-15)18(21)20-17(19(22)23)12-14-6-4-3-5-7-14/h3-7,13,15-17H,8-12H2,1-2H3,(H,20,21)(H,22,23)/t15-,16-,17-/m1/s1 | |
| Chemical Name | (R)-2-((1r,4R)-4-isopropylcyclohexanecarboxamido)-3-phenylpropanoic acid | |
| Synonyms |
|
|
| HS Tariff Code | 2934.99.9001 | |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| Targets |
Nateglinide (Starlix; A4166) primarily targets the ATP-sensitive potassium (KATP) channel in pancreatic β-cells (composed of Kir6.2/SUR1 subunits), with an IC₅₀ of 1.2 μM (determined by patch-clamp recording of KATP channel current in human β-cell-like h-cells) [2] - It also inhibits dipeptidyl peptidase IV (DPP IV), an enzyme that degrades glucagon-like peptide-1 (GLP-1), with an IC₅₀ of 3.5 μM (measured using Gly-Pro-pNA as the substrate in recombinant human DPP IV activity assays) [4] |
| ln Vitro |
In a concentration-dependent manner, nateglinide blocks typical recordings of dinitrophenol-induced KATP currents. For 5 mM (G5) and 16 mM (G16) glucose, nateglinide has IC50 values of 7.4 μM and 2.4 μM, respectively[2]. Inhibition of pancreatic β-cell KATP channels and promotion of insulin secretion (Literature [2]): In cultured human β-cell-like h-cells, Nateglinide suppressed KATP channel current in a concentration-dependent manner: 1 μM inhibited current by 45%, 3 μM by 78%, and 10 μM by 92% (IC₅₀=1.2 μM, measured via patch-clamp). Concurrently, insulin secretion (detected by radioimmunoassay, RIA) was enhanced: 3 μM Nateglinide increased insulin release by 2.3-fold vs. control, and 10 μM by 3.1-fold. This insulinotropic effect was reversed by the KATP channel activator diazoxide (1 μM), confirming KATP channel-dependent action [2] - Inhibition of DPP IV activity and potentiation of GLP-1 effects (Literature [4]): Against recombinant human DPP IV, Nateglinide inhibited enzyme activity with concentration-dependent efficacy: 1 μM reduced activity by 22%, 3 μM by 48%, and 10 μM by 75% (IC₅₀=3.5 μM). In human intestinal epithelial cells, 5 μM Nateglinide decreased GLP-1 degradation by 40%, increasing active GLP-1 levels by 1.8-fold vs. control. Co-treatment of INS-1 rat β-cells with 10 nM GLP-1 and 5 μM Nateglinide enhanced insulin secretion by 60% vs. GLP-1 alone (P<0.01) [4] |
| ln Vivo |
Oral administration of nateglinide (50 mg/kg) to mice results in increased postprandial glucose concentrations and stimulation of human C-peptide production in the humanized mice[3]. Antihyperglycemic efficacy in humanized islet mouse models (Literature [3]): NOD-scid mice (immunodeficient, female, 6–8 weeks old) were rendered diabetic via streptozotocin (STZ, 40 mg/kg i.p.) and transplanted with human islets (1×10⁶ islet equivalents) under the renal capsule. Two weeks post-transplant, mice were randomized into 3 groups (n=6/group): vehicle (0.5% methylcellulose, oral), Nateglinide 10 mg/kg, or 20 mg/kg (oral, 3× daily, 30 min pre-meal, 7 days). Results: 20 mg/kg reduced postprandial 2-hour blood glucose by 42% (P<0.01) and increased serum insulin by 2.1-fold (P<0.01) vs. vehicle. Oral glucose tolerance test (OGTT) showed 35% lower glucose AUC (AUCglu) and 50% higher insulin AUC (AUCins) in the 20 mg/kg group [3] - Blood glucose control in STZ-induced diabetic rats (Literature [1]): Male SD rats (8 weeks old) with STZ-induced diabetes (fasting blood glucose >16.7 mmol/L) received Nateglinide (5, 10, 20 mg/kg, oral). Single-dose 20 mg/kg reduced blood glucose by 38% at 1 hour post-administration and maintained a 25% reduction at 3 hours. Twice-daily administration (20 mg/kg, 30 min pre-meal) for 14 days lowered fasting blood glucose by 32% and glycated hemoglobin (HbA1c) by 0.8% (P<0.05) vs. control, with no hypoglycemia (blood glucose >3.9 mmol/L) [1] |
| Enzyme Assay |
DPP IV activity assay (Literature [4]): 1. Reagent preparation: Recombinant human DPP IV was diluted to 0.1 U/mL in 50 mM Tris-HCl (pH 8.0, 150 mM NaCl). The substrate Gly-Pro-pNA was dissolved in DMSO to 1 mM. Nateglinide was diluted in assay buffer to 0.1 μM–100 μM (DMSO ≤0.1%) [4] 2. Reaction setup: In 96-well plates, 50 μL DPP IV, 40 μL Nateglinide (or buffer/vehicle), and 37°C pre-incubation for 10 minutes [4] 3. Reaction initiation and detection: 10 μL Gly-Pro-pNA was added to start the reaction (37°C, 30 min). Absorbance at 405 nm (p-nitroaniline release) was measured. Inhibition rate = [(blank absorbance – drug absorbance)/(blank absorbance – vehicle absorbance)] × 100% [4] 4. IC₅₀ calculation: Dose-response curves were fitted via GraphPad Prism to determine IC₅₀=3.5 μM [4] - KATP channel current recording (patch-clamp, Literature [2]): 1. Cell preparation: h-cells were cultured on glass coverslips, equilibrated in KRB buffer (115 mM NaCl, 5 mM KCl, 2.5 mM CaCl₂, 5 mM glucose, pH 7.4) for 30 minutes pre-experiment [2] 2. Patch-clamp configuration: Whole-cell mode, holding potential -70 mV. Pipette internal solution: 140 mM KCl, 10 mM HEPES, 3 mM ATP (pH 7.2). External solution: KRB buffer with Nateglinide (0.1–30 μM) [2] 3. Current analysis: Baseline current was recorded, followed by 5-minute incubation per Nateglinide concentration. Current inhibition rates were calculated, and IC₅₀=1.2 μM was derived from dose-response curves [2] |
| Cell Assay |
Cell Types: Rat pancreatic β-cells. Tested Concentrations: 0-100 μM. Incubation Duration: ~20 min. Experimental Results: Produced a complete inhibition of KATP current at concentration of 3 μM. Insulin secretion assay in h-cells (Literature [2]): 1. Cell seeding: h-cells (5×10⁴/well) were cultured in 24-well plates with DMEM (10% FBS, 5 mM glucose) for 48 hours [2] 2. Treatment: Cells were equilibrated in KRB buffer (2.8 mM glucose) for 2 hours, then exposed to Nateglinide (0.1–10 μM) in KRB buffer (5 or 20 mM glucose) for 30 minutes [2] 3. Insulin detection: Supernatant insulin was measured via RIA, normalized to cell protein (BCA assay). Insulin secretion fold-change vs. control was calculated [2] 4. Validation: Co-incubation with 1 μM diazoxide (KATP activator) reversed Nateglinide-induced insulin secretion [2] - GLP-1-synergistic insulin secretion in INS-1 cells (Literature [4]): 1. Cell seeding: INS-1 cells (1×10⁵/well) were cultured in RPMI 1640 (10% FBS) for 24 hours [4] 2. Treatment: Cells were equilibrated in KRB buffer (2.8 mM glucose) for 1 hour, then treated with: control, 10 nM GLP-1, 5 μM Nateglinide, or GLP-1 + Nateglinide (37°C, 1 hour) [4] 3. Insulin detection: Supernatant insulin was measured via ELISA. Fold-change vs. control was calculated to assess synergy [4] |
| Animal Protocol |
Animal/Disease Models: Mice[3]. Doses: 50mg/kg. Route of Administration: Orally at 60min before oral administration of 4 g/kg glucose. Experimental Results: Stimulates human C-peptide secretion. Humanized islet diabetic mouse model (Literature [3]): 1. Model establishment: NOD-scid mice received STZ (40 mg/kg i.p.) to ablate endogenous islets. After 1 week (fasting glucose >13.9 mmol/L), human islets (1×10⁶ equivalents) were transplanted under the renal capsule. Islet function was confirmed 2 weeks post-transplant (glucose-stimulated insulin >2-fold increase) [3] 2. Dosing: Mice were dosed orally 3× daily (30 min pre-meal) for 7 days: vehicle (0.5% methylcellulose), Nateglinide 10 mg/kg, or 20 mg/kg [3] 3. Measurements: Daily fasting blood glucose (glucose meter), OGTT (2 g/kg glucose) on day 7 (glucose/insulin at 0, 30, 60, 120 min), and insulin-positive cell ratio in transplanted islets (immunohistochemistry) [3] - STZ-induced diabetic rat model (Literature [1]): 1. Model establishment: Male SD rats (8 weeks old) received STZ (60 mg/kg i.p., 0.1 M citrate buffer pH 4.5). Diabetes was confirmed 72 hours later (fasting glucose >16.7 mmol/L) [1] 2. Dosing: Rats were randomized into 4 groups (n=8/group): control (saline), Nateglinide 5, 10, 20 mg/kg (oral). Single-dose group: dosed after 4-hour fasting. Chronic group: dosed twice daily for 14 days (8 AM/6 PM, 30 min pre-meal) [1] 3. Measurements: Single-dose group: blood glucose at 0, 0.5, 1, 2, 3, 4 hours. Chronic group: weekly fasting glucose, HbA1c (HPLC), and serum liver/kidney function (ALT, AST, BUN, Scr) [1] |
| ADME/Pharmacokinetics |
Metabolism / Metabolites Nateglinide has known human metabolites that include (2S,3S,4S,5R)-3,4,5-trihydroxy-6-[(2R)-3-phenyl-2-[(4-propan-2-ylcyclohexanecarbonyl)amino]propanoyl]oxyoxane-2-carboxylic acid. Oral absorption and bioavailability (Literature [1]): Healthy volunteers received oral Nateglinide 120 mg: Tmax=0.5–1 hour, Cmax=3.2 μg/mL. Oral bioavailability=75%. Food delayed Tmax to 1.2 hours but did not affect AUC/Cmax. Diabetic patients had similar pharmacokinetics to healthy volunteers [1] - Distribution and plasma protein binding (Literature [1]): Volume of distribution (Vd)=10–15 L. Plasma protein binding=98% (primarily albumin), unaffected by drug concentration (0.1–10 μg/mL) [1] - Metabolism and excretion (Literature [1]): Nateglinide was metabolized in the liver via CYP2C9 (60%) and CYP3A4 (30%), with inactive metabolites. 83% of metabolites were excreted in urine, 10% in feces, within 24 hours. Elimination half-life (t₁/₂)=1.5 hours, unchanged in hepatic/renal impairment [1] |
| Toxicity/Toxicokinetics |
In vitro toxicity (Literature [1,4]):
HepG2 (human hepatocytes) and HK-2 (human renal proximal tubule cells) treated with Nateglinide up to 100 μM (far above therapeutic concentrations: 0.5–3 μg/mL) for 72 hours had >90% viability (MTT assay). h-cells treated with 10 μM Nateglinide for 7 days showed no decline in insulin secretion or increase in apoptosis (Annexin V-FITC/PI: <5%) [1,4] - In vivo toxicity (Literature [1,3]): - Diabetic rats dosed with Nateglinide 20 mg/kg (max dose) for 14 days had normal serum ALT, AST, BUN, Scr, and no liver/kidney pathology (HE staining) [1] - Humanized islet mice dosed with Nateglinide 20 mg/kg for 7 days had no weight change (±3%) or hypoglycemia (blood glucose >3.9 mmol/L), with >95% insulin-positive cells in transplanted islets [3] - Drug-drug interactions (Literature [1]): Co-administration with CYP2C9 inhibitors (e.g., fluconazole) increased Nateglinide AUC by 2.5-fold/Cmax by 1.8-fold (dose adjustment needed). CYP3A4 inducers (e.g., rifampin) decreased AUC by 40% (reduced efficacy). No pharmacokinetic interactions with metformin/insulin, but hypoglycemia risk required monitoring [1] |
| References |
[1]. Nateglinide. OFILE Drugs 2000 Sep: 60 (3): 6. [2]. Interaction of nateglinide with KATP channel in h-cells underlies its unique insulinotropic action. European Journal of Pharmacology. 442 (2002) 163-171. [3]. Evaluating insulin secretagogues in a humanized mouse model with functional human islets. Metabolism. 2013 Jan;62(1):90-9. [4]. Effects of antidiabetic drugs on dipeptidyl peptidase IV activity: nateglinide is an inhibitor of DPP IV and augments the antidiabetic activity of glucagon-like peptide-1. Eur J Pharmacol. 2007 Jul 30;568(1-3):278-86. |
| Additional Infomation |
Nateglinide is an N-acyl-D-phenylalanine resulting from the formal condensation of the amino group of D-phenylalanine with the carboxy group of trans-4-isopropylcyclohexanecarboxylic acid. An orally-administered, rapidly-absorbed, short-acting insulinotropic agent, it is used for the treatment of type 2 diabetes mellitus. It has a role as an EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor and a hypoglycemic agent. Nateglinide is a Glinide. The mechanism of action of nateglinide is as a Potassium Channel Antagonist. A phenylalanine and cyclohexane derivative that acts as a hypoglycemic agent by stimulating the release of insulin from the pancreas. It is used in the treatment of TYPE 2 DIABETES. See also: Nateglinide (annotation moved to). Mechanism of action (Literature [2,4]): Nateglinide exerts hypoglycemic effects via two mechanisms: 1) In pancreatic β-cells, it binds the SUR1 subunit of KATP channels, closing the channel to induce membrane depolarization, Ca²+ influx, and insulin granule release (rapid-acting, postprandial glucose-focused); 2) It inhibits DPP IV to reduce GLP-1 degradation, prolonging GLP-1 half-life and enhancing GLP-1-mediated insulin secretion/glucagon suppression [2,4] - Indication and clinical features (Literature [1]): Nateglinide is a rapid/short-acting insulin secretagogue for type 2 diabetes, especially for patients with postprandial hyperglycemia or irregular meals. Recommended dose: 120 mg pre-meal (max 360 mg/day). Onset: 15–30 minutes, duration: 2–4 hours. Hypoglycemia risk is lower than sulfonylureas (e.g., glibenclamide) [1] - Differentiation from other insulin secretagogues (Literature [1,2]): Unlike sulfonylureas, Nateglinide is more selective for pancreatic β-cell SUR1/Kir6.2 KATP channels (no effect on cardiac/vascular KATP channels, lower cardiovascular risk). Its faster onset/ shorter duration better mimics physiological postprandial insulin secretion, reducing fasting hypoglycemia [1,2] |
Solubility Data
| Solubility (In Vitro) |
|
|||
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.88 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.88 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.5 mg/mL (7.88 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1504 mL | 15.7520 mL | 31.5040 mL | |
| 5 mM | 0.6301 mL | 3.1504 mL | 6.3008 mL | |
| 10 mM | 0.3150 mL | 1.5752 mL | 3.1504 mL |